Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
146.47
-0.92 (-0.62%)
At close: Dec 20, 2024, 4:00 PM
147.65
+1.18 (0.81%)
After-hours: Dec 20, 2024, 6:13 PM EST
Biogen Employees
Biogen had 7,570 employees as of December 31, 2023. The number of employees decreased by 1,155 or -13.24% compared to the previous year.
Employees
7,570
Change (1Y)
-1,155
Growth (1Y)
-13.24%
Revenue / Employee
$1,269,155
Profits / Employee
$213,369
Market Cap
21.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Teva Pharmaceutical | 37,851 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
Mettler-Toledo International | 17,300 |
Illumina | 13,360 |
West Pharmaceutical Services | 10,600 |
Waters | 7,900 |
BIIB News
- 9 days ago - Private Medicare plans must cover Biogen's ALS drug, US agency says - Reuters
- 12 days ago - Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown - Benzinga
- 16 days ago - GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners - Business Wire
- 18 days ago - Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript - Seeking Alpha
- 18 days ago - Biogen expects steady growth for Alzheimer's drug Leqembi in near term - Reuters
- 4 weeks ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 4 weeks ago - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - GlobeNewsWire
- 4 weeks ago - Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Benzinga